BioTelemetry Inc. (NASDAQ:BEAT) shares traded higher over the last trading session, gaining 1.65% on 07/06/20. The shares fell to a low of $46.14 before closing at $46.31. Intraday shares traded counted 0.32 million, which was -2.0% lower than its 30-day average trading volume of 309.12K. BEAT’s previous close was $45.56 while the outstanding shares total 34.19M. The firm has a beta of 1.27, a 12-month trailing P/E ratio of 66.73, and a growth ratio of 2.67. The stock’s Relative Strength Index (RSI) is 50.46, with weekly volatility at 3.24% and ATR at 1.97. The BEAT stock’s 52-week price range has touched low of $27.35 and a $55.85 high.
Investors have identified the Diagnostics & Research company BioTelemetry Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.58 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
BioTelemetry Inc. (BEAT) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 213074000 million total, with 49091000 million as their total liabilities.
BEAT were able to record 5.72 million as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by 38.23 million. In cash movements, the company had a total of 12.7 million as operating cash flow.
Potential earnings growth for BioTelemetry Inc. (BEAT)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, BioTelemetry Inc. recorded a total of 113.03 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 8.01% coming in sequential stages and their sales for the third quarter increasing by 0.88%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 42.52 million trying to sell their products during the last quarter, with the result yielding a gross income of 70.51 million. This allows shareholders to hold on to 34.19M with the revenue now reading 0.21 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (0.43 cents a share).
Having a look at the company’s valuation, the company is expected to record 1.95 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BEAT sounds very interesting.
Is the stock of BEAT attractive?
In related news, SVP & General Counsel, Ferola Peter sold 5,065 shares of the company’s stock in a transaction that recorded on Dec 31. The sale was performed at an average price of 46.62, for a total value of 236,130. As the sale deal closes, the SVP & General Counsel, Ferola Peter now sold 44,276 shares of the company’s stock, valued at 1,728,092. In the last 6 months, insiders have changed their ownership in shares of company stock by 3.00%.
5 out of 6 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on BioTelemetry Inc.. 0 analysts has assigned a Sell rating on the BEAT stock. The 12-month mean consensus price target for the company’s shares has been set at $61.20.